Ozonized glycerin boosts skin repair and barrier proteins in preclinical tests, study finds

Table of Contents

  1. Key Highlights
  2. Introduction
  3. What is ozonized glycerin and how does it differ from standard glycerin?
  4. The study design: 3D epidermal wound models and human skin explants
  5. Faster wound closure: the data and the biological signals behind it
  6. Reinforcing the barrier: claudin‑1, desmocollin‑1, collagen III and TIMP‑1
  7. Anti‑inflammatory profile and preservation of elastin under stress
  8. Proposed mechanisms: mild oxidative signaling, ozonides and antioxidant pathways
  9. Practical implications for product developers and clinicians
  10. Safety, stability and regulatory considerations
  11. What remains unknown: limitations and the path to clinical relevance
  12. How ozonized glycerin compares with established barrier and repair actives
  13. Market and commercial potential: who would buy and why
  14. Ethical and environmental considerations
  15. Next steps for researchers and companies
  16. Critical appraisal: strengths and caveats of the NC State study
  17. How clinicians might use the information now
  18. Final perspective
  19. FAQ

Key Highlights

  • A 2026 preclinical study found ozonized glycerin accelerated wound closure and increased key barrier proteins (claudin-1, desmocollin-1) compared with standard glycerin in 3D epidermal models and human skin explants.
  • Ozonized glycerin reduced pro-inflammatory IL‑1α, increased TGF‑β1 and collagen type III/TIMP‑1 under basal conditions, while better preserving elastin during inflammatory challenge; authors call for in vivo and mechanistic follow-up.

Introduction

Glycerin is a cosmetic mainstay: inexpensive, highly hygroscopic, and widely used to hydrate the stratum corneum and improve topical formulation texture. A new paper published in Cosmetics (2026) suggests that chemically modifying glycerin by stabilizing ozone-derived species within it—so-called ozonized glycerin—can change the molecule’s biological activity in ways that matter for skin repair and barrier integrity. Researchers at North Carolina State University report faster wound closure in a 3D epidermal model, altered cytokine and growth factor secretion indicative of reduced inflammation and enhanced repair signaling, and increased expression of proteins central to epidermal cohesion in human ex vivo skin explants. The findings point to potential uses in post-treatment care and resilience-focused skincare, but the evidence remains preclinical. The study frames ozonized glycerin as a candidate ingredient that merits further testing in animal models and human trials.

The following review synthesizes the study’s methods and results, situates them within current skin biology and formulation practice, evaluates likely mechanisms of action, and outlines the experiments and regulatory steps needed to move from laboratory finding to commercial product.

What is ozonized glycerin and how does it differ from standard glycerin?

Glycerin (glycerol) is a simple trihydroxy alcohol that functions primarily as a humectant in topical products: it attracts and retains water in the stratum corneum, enhancing immediate skin hydration. Ozonized glycerin is produced by reacting ozone (O3) with glycerin to generate oxygenated adducts—commonly called ozonides or peroxides—stabilized within the glycerin matrix. Those oxygen-rich species are chemically distinct from unmodified glycerin and can release reactive oxygen species (ROS) or modified oxygenated molecules at the skin interface in a controlled manner.

Key differences relevant to formulation and biology:

  • Chemical profile: Ozonization converts some glycerin molecules into ozonides and peroxidic species. Those new species have different redox characteristics than glycerin.
  • Stability: Commercial ozonized glycerin approaches aim to stabilize ozone chemistry in a viscous glycerin carrier to allow prolonged shelf life and controlled release; gaseous ozone itself is too reactive and hazardous for direct use on skin.
  • Biological activity: The oxygenated adducts can modulate local signaling pathways by creating mild oxidative signals that prompt adaptive cellular responses, rather than producing sustained high-level oxidative damage.

The concept is not new: stabilized ozonides and peroxidic intermediates have been explored in wound care and antimicrobial contexts because oxidative species can inactivate pathogens and alter host cell signaling. The NC State study focuses on whether those altered chemistry properties translate to measurable changes in skin repair and barrier proteins compared with plain glycerin.

The study design: 3D epidermal wound models and human skin explants

The research team used two complementary preclinical models to compare ozonized glycerin (OG) and regular glycerin (G). Both models are widely used for screening topical agents before animal or human testing because they preserve tissue architecture and allow controlled experimental manipulation.

  1. 3D epidermal wound-healing model (13‑day observation)
    • A reconstructed human epidermis model with a standardized wound was treated and monitored over 13 days.
    • The primary outcome was wound closure rate; secondary outcomes included proteomic or secreted factor measurements tied to matrix remodeling and inflammatory signaling.
  2. Human ex vivo skin biopsies (4‑day observation)
    • Full-thickness human skin obtained from surgical waste or donor sources was maintained in culture and pretreated with OG or G prior to analysis.
    • The ex vivo explant model preserves native cell populations—keratinocytes, fibroblasts, resident immune cells—allowing protein expression and structural assessment of epidermal integrity markers.
  3. Inflammatory challenge: LPS model
    • To simulate an inflammatory environment, researchers applied lipopolysaccharide (LPS), a bacterial endotoxin known to evoke innate immune responses.
    • This allowed comparison of treatment effects under baseline and inflamed conditions, focusing on matrix metalloproteinase expression and extracellular matrix (ECM) preservation.

Endpoints measured:

  • Morphometric wound closure in the 3D model.
  • Cytokine and growth factor levels (e.g., IL‑1α, TGF‑β1).
  • Protein expression by immunohistochemistry or biochemical assays: claudin‑1, desmocollin‑1 (barrier proteins), collagen types I and III, TIMP‑1 (tissue inhibitor of metalloproteinases), elastin.
  • MMP‑9 levels as a marker of ECM degradation potential.

The approach provides mechanistic insight and multiple converging data points while remaining in vitro/ex vivo rather than in living organisms.

Faster wound closure: the data and the biological signals behind it

The most immediate, headline result is a modest but consistent improvement in wound closure in the 3D epidermal model treated with ozonized glycerin: roughly a 6.8% increase in closure versus glycerin alone. On its face, a single‑digit percentage change requires interpretation, but the authors paired the morphometric result with shifts in signaling molecules that provide a plausible biological explanation.

Key molecular changes tied to wound closure:

  • Decreased IL‑1α: Interleukin‑1α is a pro‑inflammatory cytokine produced by keratinocytes and other skin cells. Elevated IL‑1α promotes inflammation and can prolong tissue damage. OG treatment lowered IL‑1α secretion relative to G, suggesting a reduction in the pro‑inflammatory milieu.
  • Increased TGF‑β1: Transforming growth factor‑beta 1 is a growth factor central to tissue repair and remodeling. It stimulates fibroblast activation, ECM deposition, and keratinocyte migration. OG increased TGF‑β1 secretion, aligning with enhanced regenerative signaling.
  • Altered matrix remodeling proteins: The study reports shifts in proteins responsible for ECM turnover and remodeling—changes that favor closure and tissue reinforcement.

Biological interpretation Wound healing involves coordinated phases: hemostasis, inflammation, proliferation and remodeling. A therapy that tempers excessive inflammation while nudging reparative pathways typically supports faster, higher-quality closure. The concurrent IL‑1α reduction and TGF‑β1 increase indicate that ozonized glycerin may reduce harmful inflammation while accelerating transition to the proliferative phase, allowing keratinocyte migration and matrix deposition to proceed.

Practical perspective A 6.8% improvement in a controlled 3D model matters to formulators and dermatologists when accompanied by biochemical evidence of regenerative pathway engagement. For clinical translation, larger effect sizes in vivo or consistent benefit in human trials will be necessary, but the directionality of the molecular signals strengthens the finding beyond a simple morphometric difference.

Reinforcing the barrier: claudin‑1, desmocollin‑1, collagen III and TIMP‑1

Preservation and restoration of the epidermal barrier are central goals in dermatology and skincare. The study reports that pre‑treatment with ozonized glycerin increased the expression of two critical proteins involved in epidermal integrity: claudin‑1 and desmocollin‑1.

Why these proteins matter

  • Claudin‑1 is a core component of tight junctions in the granular layer of the epidermis. Tight junctions regulate paracellular permeability and prevent uncontrolled water loss and microbial ingress. Loss of claudin‑1 is linked to barrier dysfunction and diseases such as atopic dermatitis.
  • Desmocollin‑1 is a desmosomal cadherin involved in intercellular adhesion between keratinocytes. Desmosomes provide mechanical cohesion; reduced desmocollin expression compromises tissue strength and resilience.

ECM reinforcement signals Under basal (non‑inflamed) conditions, OG also raised collagen type III and TIMP‑1 levels:

  • Collagen III is abundant in early repair and provides a scaffold for tissue regeneration; it is associated with pliable, resilient ECM.
  • TIMP‑1 inhibits MMPs (matrix metalloproteinases), which degrade collagen and other ECM proteins. Elevated TIMP‑1 favors ECM preservation and controlled remodeling.

Taken together, these changes suggest a harmonized effect—OG appears to increase both the structural proteins that hold the epidermis together and regulators that restrain excessive ECM degradation. That combination is attractive for products aimed at barrier repair, post‑procedure recovery and resilience against environmental challenges.

Real-world relevance Barrier‑supporting ingredients such as ceramides and niacinamide are already staples for barrier repair regimens. An ingredient that specifically increases claudin‑1 and desmocollin‑1 could fill a more targeted niche by enhancing cell‑cell junctions and intercellular cohesion rather than focusing solely on lipid replenishment or stratum corneum hydration.

Anti‑inflammatory profile and preservation of elastin under stress

The team challenged explants with LPS to simulate an inflammatory insult. Under LPS, both glycerin and ozonized glycerin reduced expression of MMP‑9, a key enzyme implicated in collagen and elastin breakdown. That both treatments reduced MMP‑9 indicates glycerin’s baseline benefit extends beyond simple humectancy: it may help blunt MMP responses in skin under certain conditions.

Notable distinctions

  • Elastin preservation: OG was more effective at preserving elastin than G during the LPS challenge. Elastin is essential for skin elasticity and recoil; its loss contributes to sagging and permanence of wrinkles. Preservation of elastin under inflammatory conditions suggests potential benefits for maintaining skin resilience in contexts of oxidative or inflammatory stress.
  • Collagen type I effects: OG’s effects on collagen type I were less pronounced, indicating a selective impact on specific ECM components rather than a blanket upregulation of all structural proteins.

Clinical and cosmetic implications Inflammation drives accelerated matrix breakdown and premature skin aging. A topical agent that reduces MMP induction and preferentially preserves elastin could find utility in anti‑aging regimens and recovery products for procedures that provoke transient inflammation (e.g., lasers, microneedling). These modalities often cause temporary elastin and collagen fragmentation; interventions that limit MMP activity and preserve elastic fibers may shorten downtime and improve long‑term outcomes.

Proposed mechanisms: mild oxidative signaling, ozonides and antioxidant pathways

The study authors link their findings to earlier literature suggesting ozonized glycerin activates antioxidant pathways, though they did not directly measure those pathways here. Several plausible mechanistic hypotheses align with the observed data:

  1. Mild redox signaling triggers adaptive responses
    • Stabilized ozonides can release small amounts of ROS or peroxidic species at the tissue interface. Low levels of oxidative stress activate cytoprotective pathways, such as the Nrf2 (nuclear factor erythroid 2–related factor 2) antioxidant response, which upregulates antioxidant enzymes and can reduce inflammatory cytokine production. Activation of these pathways would fit the observed IL‑1α reduction and possible enhancement of repair processes.
  2. Direct modulation of matrix remodeling
    • Ozonized species may directly or indirectly modify the activity of proteases (e.g., MMPs) or their inhibitors (TIMPs), shifting the balance toward preservation of ECM. The observed increase in TIMP‑1 supports this idea.
  3. Cellular signaling via lipid oxidation products
    • Oxidation products can serve as signaling molecules that influence growth factor expression. Elevated TGF‑β1 secretion following OG exposure may stem from such signaling cascades.
  4. Antimicrobial and immunomodulatory contributions
    • Although the present study did not report antimicrobial assays, ozonides historically have antimicrobial properties. Reduction of low‑grade microbial triggers at the skin surface can reduce inflammation and facilitate repair.

What the study did not show The authors explicitly did not measure activation of Nrf2 or other antioxidant pathway markers in this work, nor did they quantify ROS release kinetics, ozonide stability, or penetration depth. Therefore mechanistic interpretations remain provisional and require targeted biochemical and molecular follow-up.

Practical implications for product developers and clinicians

Formulators and clinicians weighing ozonized glycerin as an ingredient should consider the study’s findings alongside formulation science, safety requirements and positioning.

Potential product categories and use cases

  • Post‑procedure care: Dressings, serums or ointments designed to accelerate recovery after dermatologic procedures (laser resurfacing, chemical peels, microneedling). The combination of reduced inflammation and enhanced barrier protein expression is particularly relevant here.
  • Barrier repair moisturizers: Products for compromised‑skin conditions (contact dermatitis, atopic tendencies, post‑procedural barrier damage) where increasing claudin‑1 and desmocollin‑1 would complement lipid restoration strategies.
  • Targeted repair serums: Formulas positioned to support ECM health and elasticity by preserving elastin and favoring collagen III deposition.
  • Resilience‑focused skincare: Pre‑conditioning treatments applied before anticipated stressors (sun exposure, environmental pollution) to strengthen barrier and reduce inflammatory responses.

Formulation considerations

  • Concentration and vehicle: The clinical effect depends on dose and release profile. Rendered ozonides must be stable in the chosen vehicle and compatible with preservatives, emulsifiers and other actives.
  • pH stability: Ozonides and peroxidic species can be pH sensitive; formulators must optimize pH to keep the chemistry stable while being skin‑compatible.
  • Packaging to prevent degradation: Reactive oxygen species and peroxides can degrade in air or when exposed to metal ions; airless dispensers, opaque containers and antioxidant buffers may be necessary.
  • Combination strategies: Pairing ozonized glycerin with ceramides, cholesterol and fatty acids could target both lipid barrier restoration and cell‑cell junction reinforcement.

Clinical deployment and claims Claims should reflect the preclinical nature of the data. Acceptable positioning might emphasize increased barrier protein expression and accelerated wound closure in preclinical models, reserving definitive efficacy claims for verified clinical endpoints in human trials.

Safety, stability and regulatory considerations

Ozone itself is a respiratory irritant and microbicidal oxidant; stabilizing ozone chemistry within a viscous glycerin carrier changes the exposure profile, but safety evaluation remains paramount.

Safety testing requirements

  • Irritation and sensitization: Standard patch testing (48–72 hours) and repeated insult patch tests in human volunteers will be necessary to rule out irritant or allergic potential, since peroxides and oxidative species can provoke contact dermatitis in susceptible individuals.
  • Phototoxicity and photosensitization: Oxidative species can sometimes increase photosensitivity; photopatch testing is advisable for topical actives with oxidative potential.
  • Cytotoxicity: In vitro cytotoxicity screens across keratinocytes and fibroblasts should precede human testing.
  • Systemic exposure: Although skin penetration of large peroxidic species is likely limited, dermal absorption, local metabolism and potential systemic exposure must be quantified, especially for leave‑on products used daily or on compromised skin.

Stability and shelf life

  • Oxidative adducts can decompose over time; manufacturers must provide stability data under accelerated and real‑time conditions, including thermal cycling and light exposure.
  • Interactions with antioxidants: Formulators often include antioxidants (vitamin E, ascorbic acid) to preserve actives; these may neutralize ozonides and negate intended biology. Compatibility studies are required.

Regulatory layer

  • Cosmetic vs drug: The intended claims determine regulatory pathway. Claims that imply tissue repair or therapeutic efficacy beyond cosmetic benefits may trigger drug or medical device classification, depending on jurisdiction. For example, an ingredient marketed to accelerate wound healing in a clinical sense may face more stringent requirements than one claimed to support skin hydration and appearance.
  • Ingredient listing and safety substantiation: Cosmetic regulations require ingredient disclosure and safety dossiers; ozonized glycerin will need a robust safety assessment compiled into a technical file (e.g., Cosmetic Product Safety Report in the EU).

Consumer perception

  • The word “ozone” has negative connotations for some consumers due to respiratory toxicity; education and clear labeling about stabilization and safety will be important.
  • Sustainability and sourcing: Transparency about manufacturing processes, absence of harmful byproducts and environmental impact of ozone generation may influence adoption by conscientious brands.

What remains unknown: limitations and the path to clinical relevance

The study presents a structured preclinical data set but leaves several critical questions open.

Limitations of the current evidence

  • Preclinical only: Both models are in vitro or ex vivo. These predict biological plausibility but do not replicate the full complexity of living skin, systemic immune responses or chronic use scenarios.
  • Timeframe constraints: The 13‑day and 4‑day observation windows provide short‑term data; long‑term effects on ECM remodeling, fibrosis risk, or cumulative irritation are unknown.
  • Mechanistic gaps: The study did not directly measure key antioxidant pathway activation (Nrf2, HO‑1, glutathione levels) or ROS kinetics.
  • Dose‑response and formulation context: The report compares OG with G but provides limited insight into concentration ranges, frequency of application and vehicle effects that will matter for product design.
  • Variability in human explant sources: Donor age, anatomical site, preexisting conditions and post‑surgical handling can influence ex vivo results; replication across diverse donor samples will strengthen conclusions.

Critical next experiments

  • In vivo animal models: Controlled wound‑healing studies in rodents or porcine models to assess closure kinetics, scarring, inflammation, systemic exposure and safety.
  • Human volunteer trials: Randomized, controlled trials for endpoints such as time to re‑epithelialization, transepidermal water loss (TEWL), subjective symptom scores, and histologic markers when tissue sampling is feasible.
  • Mechanistic assays: Quantify Nrf2 activation, antioxidant enzyme expression, ROS release profiles and ozonide metabolism to establish how OG triggers observed outcomes.
  • Penetration and pharmacokinetics: Franz diffusion cells and tape stripping to determine penetration depth and the fate of oxygenated species in epidermis and dermis.
  • Formulation matrix studies: Evaluate OG stability with typical cosmetic ingredients (preservatives, emulsifiers, common actives) to identify compatible product platforms.

How ozonized glycerin compares with established barrier and repair actives

Positioning an ingredient requires comparison to competitors. Several well‑characterized actives target hydration, barrier repair and matrix support.

Hyaluronic acid

  • Mechanism: Attracts and binds water, increases skin hydration and turgor.
  • Complementarity: Hyaluronic acid focuses on extracellular water binding; OG may complement by strengthening cell junctions and modulating repair signaling rather than acting primarily as a humectant.

Ceramides and barrier lipids

  • Mechanism: Replenish stratum corneum lipids to restore barrier function and reduce TEWL.
  • Complementarity: Ceramides rebuild lipid matrix while OG appears to increase cell‑cell junction proteins and ECM regulators; combined strategies could address both lipid and junctional components of barrier integrity.

Peptides and growth factor mimetics

  • Mechanism: Signal through receptors to promote collagen synthesis or matrix remodeling.
  • Complementarity: OG’s reported increase in TGF‑β1 and collagen III suggests potential synergy or redundancy with peptide actives; combination strategies require testing to avoid overstimulation or counterproductive interactions.

Retinoids

  • Mechanism: Promote collagen production and epidermal turnover but can cause irritation.
  • Differentiator: OG’s anti‑inflammatory and barrier‑supportive profile might make it a candidate for pairing with retinoids to reduce irritation, though interactions need empirical study.

Antioxidants (vitamin C, E)

  • Mechanism: Neutralize ROS and support collagen stabilization.
  • Compatibility: Formulation compatibility is uncertain: antioxidants may neutralize OG’s reactive species and blunt intended signaling. Strategically separating application times (e.g., alternate morning/night) could preserve functionality.

Overall, OG is not a direct substitute for these actives but could occupy a unique niche focused on modulating redox signaling to reinforce junctional proteins and preserve elastin during inflammatory stress.

Market and commercial potential: who would buy and why

Skincare and dermatologic markets prize ingredients with demonstrable mechanistic benefits that can be differentiated in product claims. Potential commercial pathways include:

  • Clinical cosmeceuticals: Post‑procedure recovery lines for dermatology clinics and medical spas, where evidence of accelerated repair and elastin preservation can support premium pricing.
  • Over‑the‑counter barrier repair products: Daily moisturizers targeting sensitive or barrier‑impaired skin; positioning should be conservative until human efficacy trials are completed.
  • Professional wound care adjuncts: Dressings or topical agents used under clinician supervision for surgical or chronic wounds, subject to stricter regulatory scrutiny.

Commercial adoption hinges on replicable human data, clear safety profiles, and scalable manufacturing. The funding link to Mediplus Pharma in the NC State study suggests industry interest in commercial translation.

Ethical and environmental considerations

Ingredient developers should assess environmental impacts of ozone generation and disposal, as well as the life cycle of the compounds produced. Transparency about manufacturing controls, worker safety during ozonation processes, and absence of harmful byproducts will matter to regulators and consumers.

From an ethical product claim perspective, companies must avoid overstating benefits based on preclinical data. Human trials with appropriate endpoints and diverse participant pools are necessary before making therapeutic or restorative claims.

Next steps for researchers and companies

To move ozonized glycerin from promising preclinical data to widely used ingredient, the field needs coordinated research and development:

  1. Mechanistic validation
    • Directly measure antioxidant pathway activation, ROS kinetics, receptor signaling and gene expression profiles tied to repair and inflammation.
  2. Dose optimization and kinetics
    • Define minimal effective concentrations, therapeutic windows and release kinetics from different vehicles.
  3. In vivo efficacy and safety
    • Conduct controlled animal studies, followed by phased human clinical trials targeting specific endpoints (wound closure time, TEWL, histologic markers, safety).
  4. Formulation and compatibility work
    • Identify compatible excipients and packaging that preserve ozonide stability without negating bioactivity.
  5. Regulatory strategy
    • Decide on cosmetic vs drug/medical device positioning, assemble safety dossiers, and engage with regulatory bodies early.
  6. Real‑world tolerability and cohort diversity
    • Test across skin types and in populations with barrier dysfunction (e.g., atopic dermatitis, aged skin) to establish benefit and safety margins.
  7. Long‑term outcome assessment
    • Measure scarring, ECM composition months after treatment, and potential cumulative effects of chronic use.

Companies that follow a rigorous, evidence‑based development path will be able to claim clinical relevance and win acceptance among clinicians and informed consumers.

Critical appraisal: strengths and caveats of the NC State study

Strengths

  • Use of complementary models: Combining a 3D wound model with human ex vivo explants provides convergent lines of evidence.
  • Multiplexed endpoints: The study examines morphological wound closure and molecular markers spanning inflammation, repair and structural proteins.
  • Clear comparisons: Directly testing ozonized glycerin against glycerin isolates the effect of ozonation chemistry from the baseline glycerin benefits.

Caveats

  • Preclinical scope: Results cannot be extrapolated to human clinical outcomes without trials.
  • Limited mechanistic assays: The study suggests antioxidant pathway involvement but lacks direct measurements to confirm.
  • Duration and scale: Short observation windows and likely limited sample sizes restrict interpretation of long‑term remodeling and generalized applicability.

Taken together, the work offers a compelling preclinical case for further investigation while highlighting the standard translational gap between bench and bedside.

How clinicians might use the information now

Clinicians who manage post‑procedural care and wound healing should note the early evidence without changing practice immediately. Practical considerations:

  • Awareness: Understanding that ozonized glycerin is emerging as a candidate topical adjunct may inform conversations with patients curious about new ingredients.
  • Evidence‑based decision making: Clinicians should await human trial data before recommending OG products for therapeutic wound care or to prevent scarring.
  • Caution with compromised skin: On patients with severe barrier defects, autoimmune conditions or sensitivity, clinicians should prioritize proven, minimally irritating therapies until OG’s safety is confirmed in clinical populations.

Final perspective

The NC State study offers a layered preclinical data set indicating that ozonized glycerin differs from standard glycerin in ways that matter biologically: accelerated closure in a 3D wound model, modulation of inflammatory and regenerative signaling, increased expression of junctional proteins and preservation of elastin during inflammatory challenge. These changes suggest practical use cases in post‑procedure recovery and barrier repair.

The path forward requires mechanistic clarity, robust in vivo and clinical trials, formulation development to preserve ozonide stability and careful safety assessment. For formulators, clinicians and investors, the ingredient warrants attention as a targeted modifier of skin repair biology—promising if validated, but not yet ready for therapeutic claims.

FAQ

Q: What exactly did the study measure to claim improved wound healing? A: The study used a reconstructed 3D epidermal wound model observed over 13 days and measured wound closure percentage. It paired morphometric data with molecular readouts, including decreased IL‑1α, increased TGF‑β1 and shifts in matrix remodeling proteins, to support the conclusion that ozonized glycerin accelerates repair processes compared with plain glycerin.

Q: Is ozonized glycerin safe for consumer use? A: Safety has not been fully established in human clinical trials. Ozone gas is harmful, but ozonized glycerin stabilizes oxygenated species within a glycerin matrix. Thorough irritation, sensitization, phototoxicity and systemic exposure testing are required before routine consumer use, especially on compromised skin.

Q: How do the molecular changes—claudin‑1, desmocollin‑1, collagen III and TIMP‑1—translate into visible benefits? A: Claudin‑1 and desmocollin‑1 strengthen tight junctions and desmosomes, improving barrier cohesion and reducing transepidermal water loss and vulnerability to irritants. Increased collagen III and TIMP‑1 suggest a tissue environment more conducive to controlled ECM deposition and resistance to excessive proteolysis. Together, these changes can support faster barrier restoration and potentially better tissue quality during repair.

Q: Does ozonized glycerin have antimicrobial effects? A: The study did not report antimicrobial testing. Historically, ozone derivatives can have antimicrobial properties. Whether stabilized ozonized glycerin retains meaningful antimicrobial activity at safe use concentrations requires targeted assays.

Q: Could ozonized glycerin replace existing barrier repair ingredients like ceramides or hyaluronic acid? A: OG addresses different aspects of skin health—cell junction integrity and modulation of repair signaling—rather than primarily replenishing lipids or binding water. It may complement rather than replace ceramides or hyaluronic acid. Formulation studies are needed to test synergistic combinations.

Q: What regulatory hurdles should companies expect? A: If marketed with therapeutic claims (e.g., “promotes wound healing”), OG‑containing products may face drug or medical device regulation depending on jurisdiction. Cosmetic claims tied to appearance or hydration generally follow less stringent routes but still require safety substantiation and truthful marketing. Early engagement with regulatory authorities and clear safety dossiers are recommended.

Q: What are the next research steps to confirm clinical utility? A: Priority steps include mechanistic assays (Nrf2 activation, ROS kinetics), dose‑finding and stability studies, in vivo animal efficacy and safety trials, and randomized controlled human trials with clinically relevant endpoints such as time to re‑epithelialization, TEWL normalization and histologic ECM assessment.

Q: Where can I read the original study? A: The research is published in Cosmetics (2026), volume 13, article 42: “Therapeutic Potential of Ozonized Glycerin in Skin Inflammation and Repair” (Ivarsson J., et al.). DOI: https://doi.org/10.3390/cosmetics13010042

Q: How should formulators handle compatibility with antioxidants or preservatives? A: Ozonide chemistry may be neutralized by antioxidants, and peroxidic species can interact with certain preservatives or metal ions. Compatibility testing is essential. Some formulation strategies may separate application of OG and antioxidant actives temporally to preserve both safety and efficacy.

Q: What consumer groups might benefit most from an OG product if clinical efficacy is confirmed? A: If validated, OG-based products could benefit users seeking faster recovery after dermatologic procedures, people with mild barrier impairment or sensitivity, and individuals aiming to preserve skin elasticity in the face of episodic inflammation. Clinical trials will define which subgroups derive meaningful benefit.